Chardan Capital Estimates Metagenomi FY2025 Earnings

Metagenomi, Inc. (NASDAQ:MGX) – Equities research analysts at Chardan Capital issued their FY2025 earnings per share estimates for Metagenomi in a research note issued to investors on Monday, March 24th. Chardan Capital analyst G. Livshits forecasts that the company will earn ($1.47) per share for the year. The consensus estimate for Metagenomi’s current full-year earnings is ($2.46) per share. Chardan Capital also issued estimates for Metagenomi’s FY2026 earnings at ($0.76) EPS.

Several other equities analysts have also recently issued reports on the company. Wells Fargo & Company decreased their price objective on Metagenomi from $25.00 to $20.00 and set an “overweight” rating for the company in a report on Tuesday, March 18th. HC Wainwright raised their price objective on shares of Metagenomi from $7.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, December 10th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Metagenomi presently has an average rating of “Moderate Buy” and an average target price of $14.40.

Metagenomi Price Performance

NASDAQ MGX opened at $1.54 on Thursday. Metagenomi has a 1 year low of $1.53 and a 1 year high of $11.13. The company has a market capitalization of $57.57 million and a PE ratio of -0.59. The company has a fifty day moving average of $2.27 and a 200 day moving average of $2.45.

Metagenomi (NASDAQ:MGX) last posted its quarterly earnings results on Monday, March 17th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01). The business had revenue of $9.61 million for the quarter, compared to analysts’ expectations of $13.18 million. Metagenomi had a negative return on equity of 43.23% and a negative net margin of 134.27%. During the same period in the prior year, the business posted ($20.05) earnings per share.

Institutional Investors Weigh In On Metagenomi

Several institutional investors and hedge funds have recently added to or reduced their stakes in MGX. Voya Investment Management LLC purchased a new stake in shares of Metagenomi during the fourth quarter worth about $37,000. Price T Rowe Associates Inc. MD acquired a new position in shares of Metagenomi during the fourth quarter valued at approximately $39,000. Rhumbline Advisers lifted its position in shares of Metagenomi by 123.3% in the fourth quarter. Rhumbline Advisers now owns 11,998 shares of the company’s stock valued at $43,000 after acquiring an additional 6,626 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Metagenomi in the fourth quarter worth approximately $43,000. Finally, BNP Paribas Financial Markets increased its position in shares of Metagenomi by 130.9% during the third quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock worth $28,000 after purchasing an additional 7,256 shares in the last quarter.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.